argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARGX
CUSIPN/A
Phone329-310-3400
Debt
Debt-to-Equity RatioN/A
Current Ratio13.16
Quick Ratio14.14
Price-To-Earnings
Trailing P/E Ratio-59.75
Forward P/E Ratio-36.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$44.74 million
Price / Sales60.15
Cash FlowN/A
Price / CashN/A
Book Value$12.12 per share
Price / Book6.90
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees73
Outstanding Shares32,170,000
Market Cap$2.89 billion
argenx (NASDAQ:ARGX) Frequently Asked Questions
What is argenx's stock symbol?
argenx trades on the NASDAQ under the ticker symbol "ARGX."
What price target have analysts set for ARGX?
6 brokers have issued 12-month price targets for argenx's stock. Their predictions range from $114.00 to $161.00. On average, they expect argenx's share price to reach $132.00 in the next twelve months. This suggests a possible upside of 57.8% from the stock's current price. View Analyst Price Targets for argenx.
What is the consensus analysts' recommendation for argenx?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx.
Who are some of argenx's key competitors?
Some companies that are related to argenx include Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN) and Momenta Pharmaceuticals (MNTA).
Who are argenx's key executives?
argenx's management team includes the folowing people:
- Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 46)
- Mr. Eric Castaldi, Chief Financial Officer (Age 54)
- Prof. Hans de Haard, Chief Scientific Officer (Age 58)
- Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 54)
- Dr. Torsten Dreier, Chief Devel. Officer (Age 54)
When did argenx IPO?
(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has argenx been receiving favorable news coverage?
Media headlines about ARGX stock have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. argenx earned a news and rumor sentiment score of 0.19 on Accern's scale. They also assigned media stories about the company an impact score of 47.58 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for argenx.
Who are argenx's major shareholders?
argenx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (9.62%), Federated Investors Inc. PA (2.56%), Redmile Group LLC (2.09%), Orbimed Advisors LLC (1.86%), Acuta Capital Partners LLC (1.41%) and BB Biotech AG (1.40%).
Which institutional investors are selling argenx stock?
ARGX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, DAFNA Capital Management LLC and JBF Capital Inc..
Which institutional investors are buying argenx stock?
ARGX stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Orbimed Advisors LLC, Dorsey Wright & Associates, BB Biotech AG, Acuta Capital Partners LLC, Granahan Investment Management Inc. MA, Connor Clark & Lunn Investment Management Ltd. and Federated Investors Inc. PA.
How do I buy shares of argenx?
Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is argenx's stock price today?
One share of ARGX stock can currently be purchased for approximately $83.65.
How big of a company is argenx?
argenx has a market capitalization of $2.89 billion and generates $44.74 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. argenx employs 73 workers across the globe.
How can I contact argenx?
argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]
MarketBeat Community Rating for argenx (NASDAQ ARGX)
MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
